Versicotides D–F, new cyclopeptides with lipid-lowering activities
نویسندگان
چکیده
منابع مشابه
New Era of Lipid-Lowering Drugs.
There are several established lipid-modifying agents, including statins, fibrates, niacin, and ezetimibe, that have been shown in randomized clinical outcome trials to reduce the risk of having an atherosclerotic cardiovascular event. However, in many people, the risk of having an event remains unacceptably high despite treatment with these established agents. This has stimulated the search for...
متن کاملStatins: Newer Roles Including Lipid Lowering Therapy
Statins are most effective pharmacologically agents to decrease total plasma cholesterol level by competitive inhibition of HMG-Co A reductase. Apart from the well-known LDL and cholesterol lowering effect, statins have been postulated to exert other beneficial effects also called pleotropic or non-lipid effects. Better understanding of various pleotropic effects of statins has prompted a new s...
متن کاملCarvedilol: A Promising Drug Combined with Lipid-lowering Medications for Patients with Hypertension and Heart Failure
Background: Statins frequently cause myopathy especially in combination with fibrates, and physical activity is considered a trigger for the muscle disorder. Elevated plasma levels of creatine kinase (CK), lactate dehydrogenase (LDH) and aldolase, are the main indicators of the severity of myopathy. Carvedilol is commonly used with lipid-lowering drugs in the management of heart failure, hypert...
متن کاملLipid lowering drugs.
likelv that L donovani was of animal origin, as were other members of the genus, and in Brazil, foxes are a significant animal reservoir. The sensitivity of the Brazilian disease to antimonial drugs does not fit with the resistance of the infantum subspecies found in Portugal. Today there are epidemics of kala-azar among poor children in favelas in cities of north eastern Brazil such as Teresin...
متن کاملPCSK9 inhibitors: A new era of lipid lowering therapy
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease (CVD). The recent American College of Cardiology and American Heart Association guidelines on lipid management emphasize treatment of individuals at increased risk for developing CVD events with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) at doses proven to reduce CVD events. However,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: RSC Adv.
سال: 2017
ISSN: 2046-2069
DOI: 10.1039/c7ra07940k